In re: Regulation of trade margins on medicines and medical devices

Hearing12 Oct 2026

Supreme Court seeks government response on capping prices of other essential medicines

The Supreme Court bench of Justices Vikram Nath and Sandeep Mehta found the Centre's response regarding the 30% trade margin cap on anti-cancer drugs to be insufficient. The court has directed the government to provide a response by October 27 regarding the potential extension of trade margin caps to other essential medicines.

Explanation in simple terms

What:: The Supreme Court asked the government to respond about limiting prices for more essential medicines.
Who:: Justices Vikram Nath and Sandeep Mehta are the judges. The Centre is the government agency involved.
When:: Reported on 12 Oct 2026.
Where:: The Supreme Court.
Why:: The court decided that the government explanation about price limits on anti-cancer drugs was not enough.
What it means:: The government must file a new response by the deadline to address wider price caps.

Dainik Bhaskar

News12 Oct 2026

'Why only cancer drugs?': SC questions Centre on trade margin cap, seeks wider price regulation

A bench of Justices Vikram Nath and Sandeep Mehta took note of the Centre's decision to impose a 30 per cent cap on trade margins for specified cancer drugs but sought to know why similar scrutiny could not extend to other medicines.

Explanation in simple terms

What:: The Supreme Court asked the government why it only limits profit margins on cancer medicines.
Who:: The Supreme Court is the judicial body, and the Centre is the government agency involved.
When:: Reported on 12 Oct 2026.
Where:: Supreme Court.
Why:: The court wants to know why price controls are not applied to a wider range of medical products.
What it means:: The court is seeking an explanation from the government regarding its current approach to setting price limits.

Mint

News12 Oct 2026

Centre Caps Cancer Drug Trade Margins At 30 Per Cent, Supreme Court Questions High Prices Of Other Medicines

The Centre has informed the Supreme Court that trade margins on anti-cancer drugs are capped at 30% of MRP. The Bench questioned why similar controls were not being considered for other medicines and medical devices, citing price differences involving cardiac stents, azithromycin and saline drip lines. The court will hear the matter again on October 27.

Explanation in simple terms

What:: The central government limited the profits companies can make when selling cancer medicine to thirty percent.
Who:: The Centre is the government agency, and the Supreme Court is the country's highest judicial body.
When:: Reported on 12 Oct 2026.
Why:: The Supreme Court raised concerns about the high costs of other medical treatments.
What it means:: The court is now examining the pricing of various other medicines beyond just cancer drugs.

Free Press Journal

News12 Oct 2026

Trade margins on cancer drugs will be capped; Supreme Court asks - why is the MRP of a 78 rupee medicine 2,850?

Trade margins on cancer drugs will be capped: Supreme Court asks - why is the MRP of a 78 rupee medicine 2,850? Centre to cap trade margins on cancer drugs

Explanation in simple terms

What:: The Supreme Court decided to limit the profit margins that companies can add to the price of cancer medicines.
Who:: The Supreme Court is the authority questioning the high prices set by drug companies.
When:: Reported on 12 Oct 2026.
Why:: The court acted because it questioned why medicine costing a small amount is sold for a much higher price.
What it means:: The court is moving to regulate and cap how much companies can increase prices for these essential drugs.

Amar Ujala

News12 Oct 2026

SC seeks wider drug price regulation, questions high markups on medicines, medical devices

Explanation in simple terms

What:: The Supreme Court asked for broader rules to control the prices of drugs and medical devices.
Who:: The Supreme Court is the body overseeing the case and reviewing how medicine prices are set.
When:: Reported on 12 Oct 2026.
Why:: The court expressed concern about the high markups, or extra costs added to the price, of medical items.
What it means:: The court is now examining how to regulate these costs more effectively in the future.

Asian News International

In re: Regulation of trade margins on medicines and medical devices

Case details

Updates

Similar Cases

Plea against Chief Election Commissioner Gyanesh Kumar

Supreme Court vs Petitioner — Tender bid assessment PIL

Supreme Court of India vs Union of India — Online Child Sexual Abuse Material (CSAM) regulation

Petitioner vs Union of India — Railway subway construction

Ashwini Kumar Upadhyay v. Union of India and Others — PIL seeking expedited NDPS trials

Ved Vignan Maha Vidya Peeth Trust v. State of Karnataka & Ors. — Land encroachment allegation challenge

Discussion

Supreme Court seeks government response on capping prices of other essential medicines

'Why only cancer drugs?': SC questions Centre on trade margin cap, seeks wider price regulation

Centre Caps Cancer Drug Trade Margins At 30 Per Cent, Supreme Court Questions High Prices Of Other Medicines

Trade margins on cancer drugs will be capped; Supreme Court asks - why is the MRP of a 78 rupee medicine 2,850?

SC seeks wider drug price regulation, questions high markups on medicines, medical devices